Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T03:48:27.348Z Has data issue: false hasContentIssue false

Exponential increase in the number of prescriptions for ADHD medication between 2012 and 2022 for in Poland.

Published online by Cambridge University Press:  27 August 2024

M. Rzeszutek*
Affiliation:
1Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland
L. Konowałek
Affiliation:
1Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

ADHD medication prescribing trends are increasing in North America and both Northern and Western Europe (Raman, Sudha R et al. Lancet Psychiatry. 2018;5(10):824-835). Methylphenidate and atomoxetine are two substances available for use in ADHD in children and adolescents in Poland. To our knowledge, there is the lack of data on prescription trends for Poland and Middle-Eastern Europe.

Objectives

The aim of the study is to estimate the increase in the total number of prescriptions for methylphenidate and atomoxetine and factors influencing it, like the impact of the proportion of prescriptions for women and for people aged 18-24 on.

Methods

Methylphenidate and atomoxetine prescription data for the period between 2012-2022 and for patients aged 5-59 were obtained from e-Health Centre, which contains data on prescribed medications in Poland. We conducted a series of linear regression models to explore the relationship between the number of prescriptions as the dependent variable and calendar year as the independent variable. Additionally, we considered two more variables: Percentage of prescriptions for women and percentage of prescriptions people aged 18 – 24. Further, we decided to run a mediation analysis to see whether the effect of calendar year was mediated by percentage of women.

Results

We analyzed data on 925,536 prescriptions for methylphenidate and atomoxetine.

The model demonstrates a robust and statistically significant ability to explain the variance in the log-transformed dependent variable (R² = 0.98, F(2, 8) = 201.14, p < 0.001). The model’s intercept, corresponding to calendar year = 0 and percentage of prescriptions for women = 0, is estimated at -93.95, with a 95% confidence interval of [-152.74, -35.15]. The t-statistic for the intercept is -3.68, and the associated p-value is 0.006, demonstrating its statistical significance.

Within this model, the effects of the independent variables are as follows:

  1. 1. Calendar year (β=0.05, t=4.07, IC95%: (0.02, 0.08), p<0,004)

  2. 2. Percentage of prescriptions for women (β=0.06, t=4.18, IC95%: (0.02, 0.09), p<0,003)

The inclusion of the percentage of prescription for people aged 18-24 doesn’t improve the model’s ability to explain the variation in the number of prescriptions.

Mediation analysis showed that the indirect effect of percentage of prescriptions for women were significant.

Conclusions

These results provide robust evidence for the predictive power of the model, with both calendar year and percentage of women emerging as statistically significant and positively associated with the log- transformed dependent variable.

Between 2012 and 2022, the number of prescriptions for methylphenidate and atomoxetine increased exponentially in Poland. The percentage of prescriptions for women significantly contributed to the increase in the total number of prescriptions for methylphenidate and atomoxetine in Poland.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.